| National Institute of Dental and Craniofacial Research

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R01 Clinical Trial Not Allowed)

RFA-DE-25-001

Notice of Correction for RFA-DE-25-004 Collaborative Science to Achieve Disruptive Innovations in Dental, Oral and Craniofacial (DOC) Research (RM1 Clinical Trial Not Allowed)

NOT-DE-25-036

Notice of Special Interest (NOSI): Advancing Precision Imaging for Enhanced Diagnosis and Treatment of Oral Lesions

NOT-DE-25-034

A microbiome community from human dental plaque.

The global HIV/AIDS response, addressing pain management in Native communities, exploring the mouth’s microbial wonders, and more.

Notice of Special Interest (NOSI): HEAL Initiative: Development and Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech

NOT-NS-24-075

Notice of NIDCR's Withdrawal of Participation in RFA-NS-22-023 HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Basic Experimental Studies with Humans Required)

NOT-DE-25-032

Pediatric HIV/AIDS Cohort Study (PHACS) (U19 Clinical Trial Not Allowed)

RFA-HD-25-003

Collaborative Science to Achieve Disruptive Innovations in Dental, Oral and Craniofacial (DOC) Research (RM1 Clinical Trial Not Allowed)

RFA-DE-25-004

Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

NOT-NS-24-015

Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

NOT-NS-24-014